Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Last Updated: March 24, 2023

Details for Patent: 8,414,921

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,414,921 protect, and when does it expire?

Patent 8,414,921 protects JANUMET and is included in one NDA.

Protection for JANUMET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has nine patent family members in six countries.

Summary for Patent: 8,414,921
Title:Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
Abstract: Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.
Inventor(s): Kamali; Ashkan (West Conshohocken, PA), Alani; Laman (Lansdale, PA), Fliszar; Kyle A. (Quakertown, PA), Ghosh; Soumojeet (Lansdale, PA), Tijerina; Monica (Doylestown, PA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:12/085,722
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,414,921
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use; Formulation;

Drugs Protected by US Patent 8,414,921

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Merck Sharp Dohme JANUMET metformin hydrochloride; sitagliptin phosphate TABLET;ORAL 022044-002 Mar 30, 2007 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Merck Sharp Dohme JANUMET metformin hydrochloride; sitagliptin phosphate TABLET;ORAL 022044-001 Mar 30, 2007 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,414,921

PCT Information
PCT FiledDecember 12, 2006PCT Application Number:PCT/US2006/047380
PCT Publication Date:July 12, 2007PCT Publication Number: WO2007/078726

International Family Members for US Patent 8,414,921

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006333151 See Plans and Pricing
Canada 2633167 See Plans and Pricing
China 101365432 See Plans and Pricing
European Patent Office 1962827 See Plans and Pricing
Japan 2009519934 See Plans and Pricing
Japan 2013047260 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.